Expand SLS Menu
SLS MENU

SLS Latest Press Releases

-- December 7, 2025 --

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 Globe Newswire 6:00 PM

-- November 12, 2025 --

SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- November 3, 2025 --

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting Globe Newswire 9:00 AM

-- October 27, 2025 --

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds Globe Newswire 8:30 AM

-- October 22, 2025 --

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum Globe Newswire 9:00 AM

-- October 13, 2025 --

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 Globe Newswire 8:00 AM

-- September 30, 2025 --

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update Globe Newswire 8:30 AM

-- September 11, 2025 --

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds Globe Newswire 8:30 AM

-- August 12, 2025 --

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- August 7, 2025 --

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification Globe Newswire 8:30 AM

-- July 15, 2025 --

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study Globe Newswire 7:45 AM
Market Data Delayed 15 Minutes